Innate Pharmaceuticals AB

115 articles about Innate Pharmaceuticals AB

• 

  23andMe, Innate Pharma Tap Antibodies to Target NK Cells for Cancer

  4/22/2024

  Drugmakers, including the genetic testing company 23andMe, are using novel approaches to stimulate NK cells’ intrinsic ability to recognize and kill tumor cells.

• Innate Pharma Announces Its Participation in Upcoming April 2024 Investor Conference

  4/9/2024

  Innate Pharma SA announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

• Innate Pharma Reports Full Year 2023 Financial Results and Business Update

  3/21/2024

  Innate Pharma SA reported its consolidated financial results for the year ending December 31, 2023.

• Innate Pharma Announces Its Participation to Upcoming Investor Conference - March 19, 2024

  3/19/2024

  Innate Pharma SA announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

• Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results

  3/14/2024

  Regulatory News: Innate Pharma SA, announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2023.

• Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma

  3/6/2024

  Innate Pharma SA announced the first patient was dosed in its Phase 1/2 multicenter trial, investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.

• Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

  3/6/2024

  Innate Pharma SA announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10 in San Diego, California.

• Innate Pharma Announces Its Participation to Upcoming March 2024 Investor Conference

  2/21/2024

  Innate Pharma SA announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below.

• Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024

  1/12/2024

  Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at January 1, 2024.

• Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

  1/4/2024

  Innate Pharma SA announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.

• Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program

  1/4/2024

  Innate Pharma SA announced that the U.S. Food and Drug Administration has lifted the partial clinical hold placed on the lacutamab IND.

• Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

  12/19/2023

  Innate Pharma SA and Sanofi announced that Sanofi has exercised its option to license a natural killer cell engager program in solid tumors from Innate’s ANKET® platform pursuant to the terms of the research collaboration and license agreement signed in December 2022.

• Innate Pharma Announces Leadership Change - December 18, 2023

  12/18/2023

  Innate Pharma SA announced that Mondher Mahjoubi has resigned from his position as Chief Executive Officer and Chairman of the Executive Board of the Company, effective as of January 2024, to pursue a senior level opportunity at a large pharmaceutical company.

• Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023

  12/11/2023

  SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi SAR443579 induced clinical benefit in patients with R/R AML with 5 complete remissions (4 CR / 1 CRi) achieved at 1 mg/kg, and was well tolerated up to doses of 6 mg/kg SAR443579 demonstrated durable responses with two responders remaining in remissi

• Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

  12/10/2023

  Innate Pharma SA announced positive final results from the Phase 2 TELLOMAK study in Sézary Syndrome.

• Innate Pharma to Host Virtual KOL Event on Lacutamab

  11/27/2023

  Innate Pharma SA announced that it will host a virtual KOL event on lacutamab, a first-in-class anti-KIR3DL2 antibody currently in development for cutaneous T-cell lymphoma and peripheral T cell lymphoma, on Tuesday, December 12, 2023, at 7:00AM PST.

• Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update

  11/14/2023

  Innate Pharma SA announced its revenues and cash position for the first nine months of 2023.

• Innate Pharma Announces Conference Call for Third Quarter 2023 Business Update

  11/7/2023

  Innate Pharma SA announced that the Company will hold a conference call on Tuesday, November 14, 2023, at 2 p.m. CET / 8 a.m. ET, to give an update on business progress during the third quarter of 2023.

• Innate Pharma Announces Its Participation to Upcoming November 2023 Investor Conferences

  10/27/2023

  Innate Pharma SA announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below.

• Innate Pharma 2024 Financial Calendar

  10/19/2023

  Innate Pharma SA released its 2024 financial calendar.